Disparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert.

ABSTRACT:

Background

Responsiveness to the Food and Drug Administration (FDA) rosiglitazone safety alert, issued on May 21, 2007, has not been examined among vulnerable subpopulations of the elderly.

Objective

To compare time to discontinuation of rosiglitazone after the safety alert between black and white elderly persons, and across sociodemographic and economic subgroups.

Research design

A cohort study.

Subjects

Medicare fee-for-service enrollees in 2007 who were established users of rosiglitazone identified from a 20% national sample of pharmacy claims.

Measures

Outcome of interest was time to discontinuation of rosiglitazone after the May alert. We modeled the number of days following the warning to the end of the days' supply for the last rosiglitazone claim

SUBMITTER: Qato DM 

PROVIDER: S-EPMC4807625 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature